Ganga Pharmaceuticals Ltd - 539680 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- PRITI KOTHARI BHAIYADesignation :- Company Secretary and Compliance Officer Ganga Pharmaceuticals Ltd - 539680 - Revised Audited Financial Results For The Half And Financial Year Ended On March 31, 2022
Revised Audited Financial Results for the half and financial year ended on March 31, 2022 Ganga Pharmaceuticals Ltd - 539680 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Non applicability of Annual Secretarial Compliance Report for the year ended March 31, 2022 Ganga Pharmaceuticals Ltd - 539680 - Financial Results For The Half And Financial Year Ended On March 31, 2022
Outcome of the Board Meeting held today i.e. on May 25, 2022- Financial Results for the Half and Financial Year ended on March 31, 2022 Ganga Pharmaceuticals Ltd - 539680 - Financial Results For The Half And Financial Year Ended On March 31, 2022
Outcome of the Board Meeting held today i.e. on May 25, 2022- Financial Results for the Half and Financial Year ended on March 31, 2022 Ganga Pharmaceuticals Ltd - 539680 - Board Meeting Intimation for Board Meeting Intimation For Considering And Approving The Audited (Standalone) Financial Results Of The Company For The Half And Financial Year Ended On March 31, 2022
Ganga Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 ,inter alia, to consider and approve Ganga Pharmaceuticals Limited has informed the BSE that a Meeting of the Board of Directors of the Company will be held on Wednesday, May 25, 2022 to inter alia, to consider and approve the Audited Financial Results of the company for the Half and Financial Year ended March 31, 2022. Ganga Pharmaceuticals Ltd - 539680 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayGanga Pharmaceuticals Ltd 2CINL99999MH1989PLC053392 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 1.91 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Priti Kothari Bhaiya Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Anagh B Sharma Designation: Chief Financial Officer EmailId: [email protected] Date: 20/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Ganga Pharmaceuticals Ltd - 539680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 Ganga Pharmaceuticals Ltd - 539680 - Compliance Certificate Under Regulation 7(3) Of LODR For The Year Ended March31, 2022
Compliance Certificate Under Regulation 7(3) Of LODR For The Year Ended March31, 2022 Ganga Pharmaceuticals Ltd - 539680 - Submission Of Compliance Certificate Pursuant To Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, LODR, 2015 For The Year Ended 30Th March, 2022.
Submission Of Compliance Certificate Pursuant To Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, LODR, 2015 For The Year Ended 30th March, 2022.